Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$237.92
-1.7%
$222.98
$96.09
$260.19
$12.45B0.61691,300 shs1.13 million shs
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$69.26
+0.9%
$69.20
$41.80
$84.94
$13.44B0.972.72 million shs4.19 million shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$23.96
+3.4%
$23.01
$13.39
$27.72
$11.58B1.695.84 million shs3.95 million shs
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
$46.99
$46.90
$40.34
$47.02
$3.54B0.686.88 million shsN/A
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-2.37%-3.95%+2.54%+49.57%+138.04%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-0.42%+2.99%-0.71%-4.16%+62.75%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-2.93%-4.21%+6.62%-8.79%+73.73%
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
0.00%0.00%0.00%0.00%+0.04%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$237.92
-1.7%
$222.98
$96.09
$260.19
$12.45B0.61691,300 shs1.13 million shs
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$69.26
+0.9%
$69.20
$41.80
$84.94
$13.44B0.972.72 million shs4.19 million shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$23.96
+3.4%
$23.01
$13.39
$27.72
$11.58B1.695.84 million shs3.95 million shs
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
$46.99
$46.90
$40.34
$47.02
$3.54B0.686.88 million shsN/A
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-2.37%-3.95%+2.54%+49.57%+138.04%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-0.42%+2.99%-0.71%-4.16%+62.75%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-2.93%-4.21%+6.62%-8.79%+73.73%
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
0.00%0.00%0.00%0.00%+0.04%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
2.95
Moderate Buy$258.958.84% Upside
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
2.84
Moderate Buy$91.0531.47% Upside
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.79
Moderate Buy$28.5519.15% Upside
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest SWTX, BBIO, AXSM, and ELAN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/18/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Boost Price TargetBuy$31.00 ➝ $32.00
6/17/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Boost Price TargetBuy$275.00 ➝ $300.00
6/16/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Lower Price TargetOutperform$106.00 ➝ $96.00
6/15/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
UpgradeStrong-Buy
6/11/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Reiterated RatingBuy$380.00
6/11/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
UpgradeReduceOverweight
6/4/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Reiterated RatingBuy
6/3/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Initiated CoverageBuy$104.00
5/28/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Boost Price TargetOverweight$94.00 ➝ $98.00
5/28/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Reiterated RatingBuy$110.00
5/26/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
DowngradeOutperformMarket Perform
(Data available from 6/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$638.50M19.18N/AN/A$1.75 per share135.95
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$502.08M27.02N/AN/A($10.77) per share-6.43
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$4.72B2.54$2.40 per share9.99$13.18 per share1.82
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
$191.59M18.48N/AN/A$6.47 per share7.26
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$183.17M-$3.73N/A50.95N/A-26.59%-267.16%-28.53%8/3/2026 (Estimated)
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$724.93M-$3.74N/A532.74N/A-124.42%N/A-65.81%8/4/2026 (Estimated)
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-$232M-$0.50N/A19.641.52-4.95%7.42%3.66%8/6/2026 (Estimated)
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
-$258.13M-$3.41N/AN/AN/A-115.60%-51.10%-43.80%N/A

Latest SWTX, BBIO, AXSM, and ELAN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2026Q1 2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$0.70-$0.84-$0.14-$0.84$178.07 million$194.52 million
5/6/2026Q1 2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.34$0.40+$0.06$0.11$1.28 billion$1.37 billion
5/4/2026Q1 2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$0.85-$1.26-$0.41-$1.26$191.10 million$191.20 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
N/AN/AN/AN/AN/A
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/AN/AN/AN/AN/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
N/AN/AN/AN/AN/A
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
2.27
1.39
1.32
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/A
1.52
1.48
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.60
2.16
1.12
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
N/A
4.33
4.18

Institutional Ownership

CompanyInstitutional Ownership
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
81.49%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
99.85%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
97.48%
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
38051.46 million40.86 millionOptionable
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
400195.86 million167.99 millionOptionable
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
9,400499.45 million493.76 millionOptionable
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
23075.35 million69.45 millionOptionable

Recent News About These Companies

SWTX Share News Today
UK Approves First Drug Option for Desmoid Tumours

New MarketBeat Followers Over Time

Media Sentiment Over Time

Axsome Therapeutics stock logo

Axsome Therapeutics NASDAQ:AXSM

$237.92 -4.05 (-1.67%)
Closing price 04:00 PM Eastern
Extended Trading
$240.50 +2.58 (+1.08%)
As of 07:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

BridgeBio Pharma stock logo

BridgeBio Pharma NASDAQ:BBIO

$69.26 +0.63 (+0.91%)
Closing price 03:59 PM Eastern
Extended Trading
$69.51 +0.25 (+0.37%)
As of 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Elanco Animal Health stock logo

Elanco Animal Health NYSE:ELAN

$23.96 +0.78 (+3.35%)
Closing price 03:59 PM Eastern
Extended Trading
$24.39 +0.43 (+1.81%)
As of 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

SpringWorks Therapeutics stock logo

SpringWorks Therapeutics NASDAQ:SWTX

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.